Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral P2Y12 platelet inhibitor used to prevent thrombotic events. It is a direct-acting, reversible antagonist of the P2Y12 adenosine diphosphate (ADP) receptor.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including myocardial infarction and stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* Prevention of stent thrombosis in patients treated with a stent following ACS.
## Adult Dosing
* **Acute Coronary Syndrome (ACS):**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for up to 12 months, or as indicated by clinical assessment.
* **History of Myocardial Infarction (MI):**
* **Maintenance Dose:** 60 mg orally twice daily. Continue for as long as clinically indicated.
* **Note:** Duration of therapy should be individualized based on patient risk factors and clinical presentation. In patients with ACS, therapy may be extended beyond 12 months if the risk of ischemic events outweighs the risk of bleeding.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required for mild to moderate renal impairment. Use with caution in severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any component of the formulation.
## Adverse Effects
* **Major Bleeding:** This is the most significant adverse effect. Can occur anywhere in the body.
* **Dyspnea:** May occur and is typically mild and transient, but can be severe.
* **Bradycardia:** Symptomatic bradycardia can occur.
* **Hyperuricemia:** Can lead to gout flares.
* **Increased serum creatinine:** Usually mild and reversible.
## Key Drug Interactions
* **CYP3A4 Substrates (e.g., simvastatin, atorvastatin):** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid concomitant use of high-dose simvastatin or atorvastatin.
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin):** May increase ticagrelor concentrations. Use with caution.
* **Strong CYP3A4 Inducers (e.g., rifampin, phenytoin):** May decrease ticagrelor concentrations. Avoid concomitant use.
* **Aspirin:** Concomitant use with aspirin increases the risk of bleeding. The recommended dose of aspirin should not exceed 100 mg when used with ticagrelor for ACS.
* **Other Antiplatelets or Anticoagulants (e.g., warfarin, heparin):** Concomitant use increases the risk of bleeding.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding, especially during the initial stages of treatment and in patients with increased bleeding risk.
* **Renal and Hepatic Function:** Monitor periodically, especially in patients with pre-existing impairment.
* **Uric Acid Levels:** Consider monitoring, particularly in patients with a history of gout or hyperuricemia.
* **Bradycardia:** Monitor heart rate, especially in patients with risk factors for bradycardia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be rapidly reversed if needed, unlike clopidogrel or prasugrel.
* The 90 mg twice-daily dose is typically used for ACS, while the 60 mg twice-daily dose is for patients with a prior MI.
* Patients should be advised to report any signs of bleeding immediately.
* Discontinuation of ticagrelor should be carefully considered as premature discontinuation significantly increases the risk of stent thrombosis and cardiovascular events.
---
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date drug information.*
